Korro Bio (KRRO) Liabilities and Shareholders Equity (2018 - 2026)

Korro Bio's Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $183.6 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 9.19% year-over-year to $183.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $639.1 million (down 30.65% YoY) and the FY2025 annual result came in at $113.5 million, down 49.83% from the prior year.
• Liabilities and Shareholders Equity was $183.6 million for Q1 2026 at Korro Bio, up from $113.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $249.6 million in Q2 2024 and bottomed at $46.3 million in Q3 2023.
• A 5-year average of $160.7 million and a median of $164.9 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity plunged 65.92% — and 2024, when it soared 425.45%.
• Korro Bio's Liabilities and Shareholders Equity stood at $73.7 million in 2022, then surged by 200.59% to $221.7 million in 2023, then grew by 2.06% to $226.2 million in 2024, then slumped by 49.83% to $113.5 million in 2025, then surged by 61.77% to $183.6 million in 2026.
• Business Quant data shows KRRO's Liabilities and Shareholders Equity at $183.6 million in Q1 2026, $113.5 million in Q4 2025, and $161.5 million in Q3 2025.